Scalper1 News
While any early-stage biotech is seen as a buyout target by the drug industry, Juno Therapeutics has been the one doing the buying. Juno (JUNO) is one of several companies developing chimeric antigen receptor (CAR) T cell therapies for cancer. This involves reprogramming the patient’s T cells, which are part of the immune system, to recognize cancer cells and kill them. Juno’s lead product, JCAR15, targets an antigen called CD19, and its Scalper1 News
Scalper1 News